First patient with advanced breast cancer receives first dose in clinical trial of GlycoMimetics’ GMI-1359
The dose-escalating study will enroll up to 12 individuals with metastatic, hormone receptor positive breast cancer with stable or minimally progressive disease, including bone metastasis. GMI-1359 is a